Piper Sandler Maintains Overweight on Madrigal Pharmaceuticals, Raises Price Target to $900
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst Yasmeen Rahimi maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight and raises the price target from $540 to $900.
Piper Sandler analyst Yasmeen Rahimi maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight and raises the price target from $540 to $900.